Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

0.48

Mkt cap

4.2M

Volume

501K

High

0.53

P/E Ratio

-0.14

52-wk high

2.92

Low

0.46

Div yield

N/A

52-wk low

0.36

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its lead drug candidate, EB-003, which targets serotonergic receptors without causing hallucinations. The drug shows potential for treating mental health conditions like depression and anxiety, with minimal cardiovascular and CNS risks. Enveric plans further testing and aims to start clinical development by the end of 2025.

Portfolio Pulse from Juan Spínelli

October 15, 2024 | 3:27 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included Gritstone Bio, Hoth Therapeutics, Lipella Pharmaceuticals, Enveric Biosciences, Oncternal Therapeutics, and Chemomab Therapeutics. Losers included Virpax Pharmaceuticals, Burning Rock Biotech, Mainz Biomed, CareDx, Inventiva, and Novo Integrated Sciences.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 12:08 pm

Enveric Biosciences has released pharmacology and safety data for its compound EB-003, which has shown the ability to target desired serotonergic receptors in vitro.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:06 pm

Companies like Mindstate Design Labs and Atai Life Sciences are developing new forms of psychedelics, termed Psychedelics 2.0, to offer mental health benefits with fewer risks. These innovations aim to address the challenges of traditional psychedelics, such as side effects and intensive monitoring requirements. Enveric Biosciences is exploring non-hallucinogenic psychedelics, potentially offering antidepressant-like benefits without extensive clinical sessions.

Portfolio Pulse from Juan Spínelli

October 04, 2024 | 7:39 pm

Enveric Biosciences presented data on its lead candidate, EB-003, at a pharmacology workshop. EB-003 shows potential as a non-hallucinogenic treatment for depression and anxiety, setting it apart from other DMT analogs.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:42 pm

Enveric Biosciences (NASDAQ:ENVB) has presented promising preclinical research on its non-hallucinogenic psychedelic compound, EB-003, for treating anxiety and depression. The company plans to file an IND application by Q3 2025 and start clinical trials by the end of 2025.

Portfolio Pulse from Jelena Martinovic

September 25, 2024 | 12:30 pm

The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

Enveric Biosciences has been granted a US patent for 'C4-Carboxylic Acid-Substituted Tryptamine Derivatives and Methods Used to Treat Brain Neurological Disorders'. This patent could enhance their intellectual property portfolio and potentially impact their market position in neurological disorder treatments.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 7:54 pm

Enveric Biosciences and Aries Science & Technology have announced the issuance of a key U.S. patent for a topical product aimed at treating radiation dermatitis. The patent strengthens Enveric's portfolio and is part of a Licensing Agreement between Enveric's subsidiary Akos Biosciences and Aries. The market opportunity for this treatment is estimated at $400 million annually.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.